9 results on '"Laar, Jan A. M."'
Search Results
2. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis
- Author
-
Abboud, Miguel R, Aytac, Sevkiye Selin, Bosse, Franziskus Johannes, Choo, Sharon, Drabko, Katarzyna, Onkologii, Klinika, Elfeky, Reem, El-Ghoneimy, Dalia Helmy, Fadoo, Zehra, Greenwood, Tatiana, Gustafsson, Britt, Hagelberg, Stefan, Hasle, Henrik, Hästbacka, Johanna, Jadrešin, Oleg, Jädersten, Martin, Kaya, Zuhre, Lecumberri, Ranon, Marques, Laura, Mushtaq, Naureen, Naqvi, Ahmed, Neves, João Farela, Nunes, Susana, Paucar, Martin, Payne, Jeanette H., Rascon, Jelena, Ruuska, Terhi Susanna, Saribeyoglu, Ebru Tugrul, Sundin, Mikael C., Svedenkrans, Jenny, Świderska, Natalia, Tedgård, Ulf, Tvedt, Tor Henrik, Ünüvar, Ayşegül, Van Laar, Jan A. M., Weitzman, Sheila, Winiarski, Jacek, Yaseen, Muhamma Zohaib, Yildiz, Mehmet, Zantomio, Daniela, Øra, Ingrid, Øverland, Torstein, Chiang, Samuel C. C., Covill, Laura E., Tesi, Bianca, Campbell, Tessa M., Schlums, Heinrich, Nejati-Zendegani, Jelve, Mördrup, Karina, Wood, Stephanie, Theorell, Jakob, Sekine, Takuya, Al-Herz, Waleed, Akar, Himmet Haluk, Belen, Fatma Burcu, Chan, Mei Yoke, Devecioglu, Omer, Aksu, Tekin, Ifversen, Marianne, Malinowska, Iwona, Sabel, Magnus, Unal, Ekrem, Unal, Sule, Introne, Wendy J., Krzewski, Konrad, Gilmour, Kimberly C., Ehl, Stephan, Ljunggren, Hans-Gustaf, Nordenskjöld, Magnus, Horne, AnnaCarin, Henter, Jan-Inge, Meeths, Marie, and Bryceson, Yenan T.
- Published
- 2024
- Full Text
- View/download PDF
3. A serum B-lymphocyte activation signature is a key distinguishing feature of the immune response in sarcoidosis compared to tuberculosis.
- Author
-
Putera, Ikhwanuliman, Schrijver, Benjamin, Kolijn, P. Martijn, van Stigt, Astrid C., ten Berge, Josianne C. E. M., IJspeert, Hanna, Nagtzaam, Nicole M. A., Swagemakers, Sigrid M. A., van Laar, Jan A. M., Agrawal, Rupesh, Rombach, Saskia M., van Hagen, P. Martin, La Distia Nora, Rina, and Dik, Willem A.
- Subjects
BLOOD proteins ,SARCOIDOSIS ,CELLULAR signal transduction ,UVEITIS ,TUBERCULOSIS - Abstract
Sarcoidosis and tuberculosis (TB) are two granulomatous diseases that often share overlapping clinical features, including uveitis. We measured 368 inflammation-related proteins in serum in both diseases, with and without uveitis from two distinct geographically separated cohorts: sarcoidosis from the Netherlands and TB from Indonesia. A total of 192 and 102 differentially expressed proteins were found in sarcoidosis and active pulmonary TB compared to their geographical healthy controls, respectively. While substantial overlap exists in the immune-related pathways involved in both diseases, activation of B cell activating factor (BAFF) signaling and proliferation-inducing ligand (APRIL) mediated signaling pathways was specifically associated with sarcoidosis. We identified a B-lymphocyte activation signature consisting of BAFF, TNFRSF13B/TACI, TRAF2, IKBKG, MAPK9, NFATC1, and DAPP1 that was associated with sarcoidosis, regardless of the presence of uveitis. In summary, a difference in B-lymphocyte activation is a key discriminative immunological feature between sarcoidosis/ocular sarcoidosis (OS) and TB/ocular TB (OTB). Sarcoidosis patients exhibit higher level of serum B cell activation signature compared to tuberculosis, regardless of uveitis manifestation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring.
- Author
-
van Bilsen, Kiki, Vergouwen, Daphne P. C., van Velthoven, Mirjam E. J., Missotten, Tom O. A. R., Rombach, Saskia M., van Zelm, Menno C., Berkowska, Magdalena A., van Hagen, P. Martin, Kuijpers, Robert W. A. M., and van Laar, Jan A. M.
- Subjects
B cells ,SCLERITIS ,RITUXIMAB ,REFRACTORY materials - Abstract
Purpose: We report the long-term effect of rituximab (RTX) in scleritis and determine the value of B-cell monitoring for the prediction of relapses. Methods: We retrospectively studied 10 patients with scleritis, who were treated with RTX. Clinical characteristics were collected, and blood B-cell counts were measured before the start of RTX, and at various time points after treatment. Results: Clinical activity of scleritis decreased after RTX treatment in all patients within a median time of 8 weeks (range 3–13), and all reached remission. The median follow-up was 101 months (range 9–138). Relapses occurred in 6 out of 10 patients. All relapses, where B-cell counts were measured (11 out of 19), were heralded by returning B cells. However, B cells also returned in patients with long-term remissions. Conclusions: RTX is a promising therapeutic option for scleritis. Recurrence of B cells after initial depletion does not always predict relapse of scleritis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. A dens fracture case solved
- Author
-
Oei, Ling, Li, Jiawei, Karim, A. Faiz, Verdijk, Robert M., Oei, Edwin H. G., van Laar, Jan A. M., Ten Cate, David, Haitsma, Iain, Monserez, Dominiek A., Zillikens, M. Carola, Oei, Ling, Li, Jiawei, Karim, A. Faiz, Verdijk, Robert M., Oei, Edwin H. G., van Laar, Jan A. M., Ten Cate, David, Haitsma, Iain, Monserez, Dominiek A., and Zillikens, M. Carola
- Abstract
Graphical Abstract
- Published
- 2024
6. Increased serum interferon activity in sarcoidosis compared to that in tuberculosis: Implication for diagnosis?
- Author
-
Schrijver B, Göpfert J, La Distia Nora R, Putera I, Nagtzaam NMAN, Smits Te Nijenhuis MAW, van Rijswijk ALCT, Ten Berge JCEM, van Laar JAM, van Hagen PM, and Dik WA
- Abstract
Objectives: In this study, we measured serum interferon (IFN) levels and activity in patients with sarcoidosis and tuberculosis (TB) with and without uveitis. We aimed to understand the role of IFN in the pathophysiology of both conditions and explore its potential as a discriminating marker for these clinically similar diseases., Methods: Sera from an Indonesian TB and a Dutch sarcoidosis cohort were used in the analysis. IFNα2 and IFNγ concentrations were measured using Simoa® and Luminex assays, respectively. Serum IFN activity was assessed by incubating THP-1 cells with patient serum and measuring IFN-stimulated gene transcription using qPCR. Anti-IFNα2 and IFNγ autoantibodies were detected via Luminex assay and tested for neutralizing capacity using a flow cytometry-based signal transducer and activator of transcription (STAT) 1 phosphorylation inhibition assay., Results: IFNα2 was detected in 74 % and 64 % of patients with sarcoidosis and pulmonary TB, respectively, while IFNγ was found in 78 % and 23 % of patients with sarcoidosis and TB, respectively. For uveitis cases specifically, IFNα2 was detected in 85 % of sarcoid uveitis (SU) and 33 % of tubercular uveitis (TBU) cases. Similarly, IFNγ was detected in 69 % of SU and 17 % of TBU cases. IFNγ serum concentrations were higher in sarcoidosis than that in TB patients ( p < 0.0001). Focusing on patients with uveitis, SU showed increased IFNα2 ( p = 0.004) and IFNγ ( p < 0.002) serum concentrations compared to that in TBU. Notably, TBU displayed significantly reduced IFNα2 concentrations compared to that in healthy controls ( p = 0.006). These results align with the increased interferon stimulated gene (ISG) transcriptional upregulation observed in THP-1 cells stimulated with serum from patients with sarcoidosis. Elevated levels of non-neutralizing anti-IFN autoantibodies were observed in patients with TB; however, these levels were similar to those observed in geographically matched healthy Indonesian controls., Conclusion: Our results suggest decreased serum levels and activity of type I and II IFN in TB compared to those in sarcoidosis. This is indicative of distinct pathophysiological processes in these highly clinically similar diseases. We propose that the assessment of serum IFN levels and IFN activity has the potential to distinguish between sarcoidosis/SU and TB/TBU., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
7. Somatostatin analogues as a treatment option for cystoid maculopathy in retinitis pigmentosa.
- Author
-
Heutinck PAT, van den Born LI, van Laar JAM, van Hagen PM, Smailhodzic D, Meester-Smoor MA, Klaver CCW, Verhoeven VJM, and Thiadens AAHJ
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Adult, Peptides, Cyclic therapeutic use, Octreotide therapeutic use, Octreotide administration & dosage, Treatment Outcome, Macular Edema drug therapy, Macular Edema etiology, Retinitis Pigmentosa drug therapy, Somatostatin analogs & derivatives, Somatostatin therapeutic use, Visual Acuity drug effects, Tomography, Optical Coherence
- Abstract
Aims: This study aimed to evaluate the effectiveness of somatostatin analogues (SA) for cystoid maculopathy (CM) in retinitis pigmentosa (RP) patients., Materials and Methods: In this retrospective case series, clinical and imaging characteristics of 28 RP patients with CM, unresponsive to carbonic anhydrase inhibitors, were collected from medical charts. All patients received SA treatment as an alternative (octreotide long-acting release at 20 mg/month or 30 mg/month, or lanreotide at 90 mg/month or 120 mg/month). Outcome measures were mean reduction in foveal thickness (FT) and foveal volume (FV) and mean increase in best-corrected visual acuity at 3, 6 and 12 months of treatment initiation. Linear mixed models were used to calculate the effectiveness over time., Results: 52 eyes of 28 RP patients were included; 39% were male. The median age at the start of treatment was 39 years (IQR 30-53). Median follow-up was 12 months (range 6-12). From baseline to 12 months, the mean FT decreased from 409±136 µm to 334±119 µm and the mean FV decreased from 0.31±0.10 mm
3 to 0.25±0.04 mm3 . Linear mixed model analyses showed a significant decrease in log FT and log FV at 3, 6 and 12 months after the start of treatment compared with baseline measurements (p<0.001, p<0.001, p<0.001). Mean best-corrected visual acuity did not increase significantly (0.46±0.35 logMAR to 0.45±0.38 logMAR after 12 months)., Discussion: SA may be an effective alternative treatment to reduce CM in RP patients., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2024
- Full Text
- View/download PDF
8. A dens fracture case solved.
- Author
-
Oei L, Li J, Karim AF, Verdijk RM, Oei EHG, van Laar JAM, Ten Cate D, Haitsma I, Monserez DA, and Zillikens MC
- Subjects
- Humans, Male, Female, Tomography, X-Ray Computed, Spinal Fractures diagnostic imaging, Spinal Fractures etiology, Odontoid Process injuries, Odontoid Process diagnostic imaging
- Published
- 2024
- Full Text
- View/download PDF
9. Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis.
- Author
-
Van Laar JAM
- Subjects
- Humans, Nitriles, Pyrimidines, Cytokine Release Syndrome drug therapy, Cytokine Release Syndrome etiology, Lymphohistiocytosis, Hemophagocytic drug therapy, Lymphohistiocytosis, Hemophagocytic etiology, Pyrazoles
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.